LNTH icon

Lantheus

91.47 USD
-0.11
0.12%
At close Jan 17, 4:00 PM EST
After hours
91.47
+0.00
0.00%
1 day
-0.12%
5 days
-4.53%
1 month
-1.28%
3 months
-20.91%
6 months
-24.78%
Year to date
3.01%
1 year
65.50%
5 years
383.46%
10 years
1,251.11%
 

About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Employees: 834

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

84% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 56

67% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]

60% more call options, than puts

Call options by funds: $93.8M | Put options by funds: $58.8M

39% more capital invested

Capital invested by funds: $5.57B [Q2] → $7.71B (+$2.15B) [Q3]

9% more funds holding

Funds holding: 449 [Q2] → 491 (+42) [Q3]

1.45% more ownership

Funds ownership: 100.1% [Q2] → 101.55% (+1.45%) [Q3]

11% less repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 178

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$112
22%
upside
Avg. target
$125
37%
upside
High target
$143
56%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
JMP Securities
David Turkaly
36% 1-year accuracy
9 / 25 met price target
22%upside
$112
Market Outperform
Reiterated
14 Jan 2025
Goldman Sachs
Paul Choi
30% 1-year accuracy
3 / 10 met price target
56%upside
$143
Buy
Initiated
18 Dec 2024
Truist Securities
Richard Newitter
79% 1-year accuracy
33 / 42 met price target
31%upside
$120
Buy
Reiterated
8 Nov 2024

Financial journalist opinion

Based on 3 articles about LNTH published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market
Enhances Lantheus' growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's Disease
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market
Positive
Seeking Alpha
2 weeks ago
Lantheus Holdings: Powerhouse Potential In 2025
Lantheus Holdings is a strong buy due to its dominant market position and promising growth prospects in radiopharmaceuticals and Alzheimer's diagnostics. PYLARIFY, Lantheus' top revenue generator, is projected to reach $2.5 billion by 2030, driven by its superior PSMA PET imaging technology. DEFINITY holds an 80% market share in ultrasound imaging, with the market expected to nearly double, further solidifying Lantheus' financial stability.
Lantheus Holdings: Powerhouse Potential In 2025
Positive
The Motley Fool
3 weeks ago
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the market this year: Lantheus (LNTH -1.26%) and Synopsys (SNPS -0.99%).
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
Positive
Seeking Alpha
1 month ago
Lantheus Holdings: A Growing Business With Dominant Market Share
Lantheus Holdings (LNTH) is a profitable company with strong products like PYLARIFY and DEFINITY, both showing double-digit growth and dominant market share. Management has demonstrated excellent execution, particularly with PYLARIFY, which is on track to exceed $1 billion in sales by Q4 2024. The company is financially robust, with nearly $1 billion in cash, minimal debt, and strong operating cash flow, positioning it well for acquisitions.
Lantheus Holdings: A Growing Business With Dominant Market Share
Neutral
The Motley Fool
2 months ago
Why Lantheus Holdings Stock Won Big on Wednesday
Why Lantheus Holdings Stock Won Big on Wednesday
Why Lantheus Holdings Stock Won Big on Wednesday
Neutral
GlobeNewsWire
2 months ago
Lantheus Announces Share Repurchase Program
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months.
Lantheus Announces Share Repurchase Program
Neutral
GlobeNewsWire
2 months ago
Lantheus to Present at the Jefferies London Healthcare Conference
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20.
Lantheus to Present at the Jefferies London Healthcare Conference
Neutral
GlobeNewsWire
2 months ago
Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Company continues to commend CMS for recognizing the value of and ensuring broad patient access to specialized diagnostic radiopharmaceuticals. With PYLARIFY® (piflufolastat F 18) on track to exceed $1 billion in sales in 2024, Lantheus reaffirms its 2025 outlook for PYLARIFY as a blockbuster brand that will continue to be the clear standard and #1 ordered PSMA PET imaging agent in the U.S.
Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025
Positive
Seeking Alpha
2 months ago
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity.
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Neutral
Seeking Alpha
2 months ago
Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning.
Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™